SANUWAVE Health (SNWV) 10-K 30 Mar 16 2015 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Mar. 23, 2016	Jun. 30, 2015
Entity Registrant Name	SANUWAVE Health, Inc.
Entity Central Index Key	1,417,663
Trading Symbol	snwv
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding (in shares)		96,000,308
Entity Public Float			$ 9.5
Document Type	10-K
Document Period End Date	Dec. 31, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	FY
Amendment Flag	false

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Convertible Preferred Stock [Member]
STOCKHOLDERS' DEFICIT
PREFERRED STOCK, SERIES A CONVERTIBLE, par value $0.001, 6,175 authorized; 6,175 shares issued and 0 and 1,165 shares outstanding at December 31, 2015 and 2014, respectively (Note 9)		$ 1
Undesignated Preferred Stock [Member]
STOCKHOLDERS' DEFICIT
PREFERRED STOCK, SERIES A CONVERTIBLE, par value $0.001, 6,175 authorized; 6,175 shares issued and 0 and 1,165 shares outstanding at December 31, 2015 and 2014, respectively (Note 9)
Cash and Cash Equivalents, at Carrying Value	$ 152,930	$ 3,547,071
Accounts receivable, net of allowance for doubtful accounts of $8,963 in 2015 and $15,018 in 2014	74,454	86,404
Inventory, net (Note 3)	284,908	271,871
Prepaid expenses	123,988	128,550
TOTAL CURRENT ASSETS	636,280	4,033,896
PROPERTY AND EQUIPMENT, at cost, less accumulated depreciation	4,228	7,840
OTHER ASSETS	11,097	11,106
INTANGIBLE ASSETS, at cost, less accumulated amortization (Note 4)	306,756	613,513
TOTAL ASSETS	958,361	4,666,355
Accounts payable	509,266	231,840
Accrued expenses (Note 5)	359,374	369,456
Accrued employee compensation	241,542	2,226
Interest payable, related parties (Note 6)	$ 239,803	81,864
Notes Payable, Related Parties, Current		5,372,743
Warrant liability (Note 2)	$ 138,100	159,626
TOTAL CURRENT LIABILITIES	1,488,085	$ 6,217,755
Notes Payable, Related Parties, Noncurrent	5,348,112
TOTAL LIABILITIES	$ 6,836,197	$ 6,217,755
COMMITMENTS AND CONTINGENCIES (Note 11)
COMMON STOCK, par value $0.001, 350,000,000 shares authorized; 63,056,519 issued and outstanding at December 31, 2015; 150,000,000 shares authorized; 60,726,519 issued and outstanding at December 31, 2014 (Note 8)	$ 63,057	$ 60,727
ADDITIONAL PAID-IN CAPITAL	87,086,677	86,584,472
ACCUMULATED DEFICIT	(92,994,408)	(88,184,123)
ACCUMULATED OTHER COMPREHENSIVE LOSS	(33,162)	(12,477)
TOTAL STOCKHOLDERS' DEFICIT	(5,877,836)	(1,551,400)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$ 958,361	$ 4,666,355

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Convertible Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Preferred Stock, Shares Authorized	6,175	6,175
Preferred stock, shares issued (in shares)	6,175	6,175
Preferred Stock, Shares Outstanding	0	1,165
Undesignated Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Preferred Stock, Shares Authorized	4,993,825	4,993,825
Preferred stock, shares issued (in shares)	0	0
Preferred Stock, Shares Outstanding	0	0
Accounts receivable, allowance for doubtful accounts	$ 8,963	$ 15,018
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	350,000,000	150,000,000
Common stock, shares issued (in shares)	63,056,519	60,726,519
Common stock, shares outstanding (in shares)	63,056,519	60,726,519

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Accretion of Debt Discount on Convertible Promissory Note [Member]
OTHER (INCOME) EXPENSE
Accretion of debt discount on convertible promissory note (Note 9)		$ (12,776)
REVENUES	$ 965,501	847,367
COST OF REVENUES	284,962	219,975
GROSS PROFIT	680,539	627,392
Research and development	2,172,819	3,000,807
General and administrative	2,735,129	3,269,033
Depreciation	3,612	14,286
Amortization of Intangible Assets	306,757	$ 306,756
Gain on sale of assets	(100,000)
TOTAL OPERATING EXPENSES	5,118,317	$ 6,590,882
OPERATING LOSS	(4,437,778)	(5,963,490)
Gain on warrant valuation adjustment (Note 2)	58,515	458,857
Interest expense, net	(399,832)	$ (433,775)
Amortization of debt discount	(12,358)
Interest expense on 18% Convertible Promissory Notes (Note 9)		$ (7,168)
Accretion of debt discount on convertible promissory note (Note 9)		(12,776)
Loss on foreign currency exchange	(18,832)	(15,728)
TOTAL OTHER EXPENSE	(372,507)	(10,590)
NET LOSS	(4,810,285)	(5,974,080)
OTHER COMPREHENSIVE LOSS
Foreign currency translation adjustments	(20,685)	(19,165)
TOTAL COMPREHENSIVE LOSS	$ (4,830,970)	$ (5,993,245)
LOSS PER SHARE:
Net loss - basic and diluted (in dollars per share)	$ (0.08)	$ (0.12)
Weighted average shares outstanding - basic and diluted (in shares)	63,025,202	48,212,910

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Deficit - USD ($)	Convertible Preferred Stock [Member]Preferred Stock [Member]	Convertible Preferred Stock [Member]Common Stock [Member]	Convertible Preferred Stock [Member]Additional Paid-in Capital [Member]	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Balances (in shares) at Dec. 31, 2013					37,984,182
Balances at Dec. 31, 2013					$ 37,984	$ 76,037,490	$ (82,210,043)	$ 6,688	$ (6,127,881)
Net Income (Loss) Attributable to Parent							(5,974,080)		(5,974,080)
Stock Issued During Period, Shares, New Issues | Private Placements [Member]				6,175	6,210,000
Stock Issued During Period, Value, New Issues | Private Placements [Member]				$ 6	$ 6,210	7,998,551			8,004,767
Shares issued in 18% Convertible Promissory Notes conversion (in shares)	(5,010)	10,020,000			1,644,337
Shares issued in 18% Convertible Promissory Notes conversion	$ (5)	$ 10,020	$ (10,015)		$ 1,645	772,549			774,194
Shares issued in related party subscription agreement (in shares)					3,600,000
Shares issued in related party subscription agreement					$ 3,600	896,400			900,000
Stock Issued During Period, Shares, Issued for Services					1,208,000
Stock Issued During Period, Value, Issued for Services					$ 1,208	741,942			$ 743,150
Shares issued for stock option exercise (in shares)					60,000				60,000
Shares issued for stock option exercise					$ 60	12,540			$ 12,600
Stock-based compensation - options						135,015			135,015
Foreign currency translation adjustment								(19,165)	(19,165)
Balances (in shares) at Dec. 31, 2014				1,165	60,726,519
Balances at Dec. 31, 2014				$ 1	$ 60,727	86,584,472	(88,184,123)	(12,477)	(1,551,400)
Net Income (Loss) Attributable to Parent							(4,810,285)		(4,810,285)
Shares issued in 18% Convertible Promissory Notes conversion (in shares)	(1,165)	2,330,000
Shares issued in 18% Convertible Promissory Notes conversion	$ (1)	$ 2,330	$ (2,329)
Stock-based compensation - options						504,534			504,534
Foreign currency translation adjustment								(20,685)	(20,685)
Balances (in shares) at Dec. 31, 2015					63,056,519
Balances at Dec. 31, 2015					$ 63,057	$ 87,086,677	$ (92,994,408)	$ (33,162)	$ (5,877,836)

Consolidated Statements of Sto6

Consolidated Statements of Stockholders' Deficit (Parentheticals)	Dec. 31, 2014
Retained Earnings [Member]
Convertible promissory note rate	18.00%

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
18% Convertible Promissory Notes [Member]
Adjustments to reconcile loss from continuing operations to net cash used by operating activities
Accrued interest on 18% Convertible Promissory Notes		$ 7,168
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from Convertible Debt		$ 815,000
Disposal Group, Held-for-sale, Not Discontinued Operations [Member]
CASH FLOWS FROM INVESTING ACTIVITIES
Proceeds from sale of assets	$ 100,000
Net Income (Loss) Attributable to Parent	(4,810,285)	$ (5,974,080)
Amortization of Intangible Assets	306,757	306,756
Depreciation	3,612	14,286
Change in allowance for doubtful accounts	(6,055)	(28,264)
Stock-based compensation - employees, directors and advisors	504,534	135,015
Stock issued for consulting services		$ 743,150
Gain on sale of assets	(100,000)
Fair Value Adjustment of Warrants	(58,515)	$ (458,857)
Amortization of debt discount	12,358
Accretion of debt discount on a convertible promissory note		$ 12,776
Accounts receivable - trade	18,005	81,596
Inventory	(13,037)	(25,865)
Prepaid expenses	4,562	(53,530)
Other	9	338
Accounts payable	277,426	(703,188)
Accrued expenses	(10,082)	(494,116)
Accrued employee compensation	239,316	(137,876)
Interest payable, related parties	157,939	(81,865)
Promissory notes - accrued interest		(21,813)
NET CASH USED BY OPERATING ACTIVITIES	(3,473,456)	(6,678,369)
Purchase of property and equipment		(8,859)
NET CASH PROVIDED BY (USED BY) INVESTING ACTIVITIES	100,000	(8,859)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from Issuance of Private Placement		8,562,500
Proceeds from sale of capital stock - subscription agreement		900,000
Proceeds from Convertible Debt		325,000
Proceeds from employee stock option exercise		12,600
Payments of principal on convertible promissory notes		(450,000)
Payments of principal on promissory notes		(90,000)
Payments of principal on capital lease		(3,951)
NET CASH PROVIDED BY FINANCING ACTIVITIES		10,071,149
EFFECT OF EXCHANGE RATES ON CASH	(20,685)	(19,165)
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	(3,394,141)	3,364,756
CASH AND CASH EQUIVALENTS, BEGINNING OF YEAR	3,547,071	182,315
CASH AND CASH EQUIVALENTS, END OF YEAR	152,930	3,547,071
SUPPLEMENTAL INFORMATION
Cash paid for interest	$ 242,904	$ 539,669

Consolidated Statements of Cas8

Consolidated Statements of Cash Flows (Parentheticals)	Dec. 31, 2014
18% Convertible Promissory Notes [Member]
Convertible promissory note rate	18.00%

Note 1 - Going Concern

Note 1 - Going Concern	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1. Going Concern As shown in the accompanying consolidated financial statements, SANUWAVE Health, Inc. and subsidiaries (the “Company”) incurred a net loss of $4,810,285 and $5,974,080 during the years ended December 31, 2015 and 2014, respectively, and the net cash used by operating activities was $3,473,456 and $6,678,369, respectively . As of December 31, 2015, the Company had a net working capital deficit of $851,805, total stockholders’ deficit of $5,877,836 and cash and cash equivalents of $152,930 . These factors create an uncertainty about the Company’s ability to continue as a going concern. The Company does not currently generate significant recurring revenue and will require additional capital during or before the third quarter of 2016. Although no assurances can be given, management of the Company believes that existing capital resources should enable the Company to fund operations into the third quarter of 2016. The continuation of the Company’s business is dependent upon raising additional capital during or before the third quarter of 2016 to fund operations. Management’s plans are to obtain additional capital in 2016 through investments by strategic partners for market opportunities, which may include strategic partnerships or licensing arrangements, or raise capital through the conversion of outstanding warrants, the issuance of common or preferred stock, securities convertible into common stock, or secured or unsecured debt. These possibilities, to the extent available, may be on terms that result in significant dilution to the Company’s existing shareholders. Although no assurances can be given, management of the Company believes that potential additional issuances of equity or other potential financing transactions as discussed above should provide the necessary funding for the Company to continue as a going concern. If these efforts are unsuccessful, the Company may be forced to seek relief through a filing under the U.S. Bankruptcy Code. The consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
Significant Accounting Policies [Text Block]	2. Summary of significant accounting policies Description of the business ® The significant accounting policies followed by the Company are summarized below: Foreign currency translation Foreign Currency Matters Principles of consolidation Estimates Cash and cash equivalents Concentration of credit risk and limited suppliers We depend on suppliers for product component materials and other components that are subject to stringent regulatory requirements. We currently purchase most of our product component materials from single suppliers and the loss of any of these suppliers could result in a disruption in our production. If this were to occur, it may be difficult to arrange a replacement supplier because certain of these materials may only be available from one or a limited number of sources. In addition, establishing additional or replacement suppliers for these materials may take a substantial period of time, as certain of these suppliers must be approved by regulatory authorities. Accounts receivable Inventory The Company analyzes its inventory levels and writes down inventory that has, or is expected to, become obsolete. Intangible assets T he Company regularly reviews intangible assets to determine if facts and circumstances indicate that the useful life is shorter than the Company originally estimated or that the carrying amount of the assets may not be recoverable. Factors the Company considers important and could trigger an impairment review include the following: ● Significant delays or obstacles encountered in the dermaPACE device clinical trial and PMA application; ● Significant changes in the manner in which the Company uses its assets or significant changes in the Company’s overall business strategy; and ● Significant underperformance of the Company’s assets relative to future operating results. If such facts and circumstances exist, the Company assesses the recoverability of the intangible assets by comparing the projected undiscounted net cash flows associated with the related asset or group of assets over their remaining lives against their respective carrying amounts. If recognition of an impairment charge is necessary, it is measured as the amount by which the carrying amount of the intangible asset exceeds its fair value. Fair value of financial instruments The Company has adopted ASC 820-10, Fair Value Measurements The ASC 820-10 hierarchy ranks the quality and reliability of inputs, or assumptions, used in the determination of fair value and requires financial assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories: Level 1 - Observable inputs that reflect quoted prices (unadjusted) in active markets for identical assets and liabilities; Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly; and Level 3 - Unobservable inputs that are not corroborated by market data, therefore requiring the Company to develop its own assumptions. The following table sets forth a summary of changes in the fair value of the derivative liability for the year ended December 31, 2015: Warrant Liability Balance at December 31, 2014 $ 159,626 New issuances 36,989 Change in fair value (58,515 ) Balance at December 31, 2015 $ 138,100 The Company accounts for derivative instruments under ASC 815, Accounting for Derivative Instruments and Hedging Activities The Company’s notes payable, related parties had an aggregate outstanding principal balance of $5,348,112, net of $24,631 debt discount at December 31, 2015 and $5,372,743 at December 31, 2014, respectively. Interest accrues on the notes at a rate of eight percent per annum, effective June 15, 2015. The fair value was determined using estimated future cash flows discounted at current rates, which is a Level 3 measurement. The estimated fair value of the Company’s notes payable, related parties was $4,844,792 and $5,221,985 at December 31, 2015 and 2014, respectively. Impairment of long-lived assets Revenue recognition Shipping and handling costs I ncome taxes Income Taxes . Deferred tax assets and liabilities are determined based on differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is provided for the deferred tax assets, including loss carryforwards, when it is more likely than not that some portion or all of a deferred tax asset will not be realized. A provision of ASC 740, Income Taxes The Company will recognize in income tax expense interest and penalties related to income tax matters. For the years ended December 31, 2015 and 2014, the Company did not have any amounts recorded for interest and penalties. Loss per share Earnings Per Share To the extent that securities are “anti-dilutive,” they are excluded from the calculation of diluted net income (loss) per share. As a result of the net loss for the years ended December 31, 2015 and 2014, respectively, all potentially dilutive shares were anti-dilutive and therefore excluded from the computation of diluted net loss per share. The anti-dilutive equity securities totaled 48,376,071 shares and 60,100,368 shares at December 31, 2015 and 2014, respectively. Comprehensive income Comprehensive Income Stock-based compensation Compensation – Stock Compensation Research and d evelopment Recent pronouncements In May 2014, the FASB issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers Revenue from Contracts with Customers (Topic 606) In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements – Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern In April 2015, the FASB issued ASU 2015-03, Interest-Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs In July 2015, the FASB issued Accounting Standards Update No. 2015-11, Simplifying the Measurement of Inventory In November 2015, the FASB issued ASU 2015-17, Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842)

Note 3 - Inventory

Note 3 - Inventory	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
Inventory Disclosure [Text Block]	3. Inventory Inventory consists of the following at December 31, 2015 and 2014: 2015 2014 Inventory - finished goods $ 290,623 $ 263,027 Inventory - parts 87,450 92,744 Gross inventory 378,073 355,771 Provision for losses and obsolescence (93,165 ) (83,900 ) Net inventory $ 284,908 $ 271,871

Note 4 - Intangible Assets

Note 4 - Intangible Assets	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
Intangible Assets Disclosure [Text Block]	4. Intangible assets Intangible assets consist of the following at December 31, 2015 and 2014: 2015 2014 Patents, at cost $ 3,502,135 $ 3,502,135 Less accumulated amortization (3,195,379 ) (2,888,622 ) Net intangible assets $ 306,756 $ 613,513 Amortization expense was $306,757 and $306,756 for the years ended December 31, 2015 and 2014, respectively. The amortization policies followed by the Company are described in Note 2. Amortization expense for the future years is summarized as follows: Years ending December 31, Amount 2016 306,756 Total $ 306,756 The weighted average amortization period for intangible assets is as follows: Amount Weighted Average Period (Years) Patents $ 3,502,135 11.4

Note 5 - Accrued expenses

Note 5 - Accrued expenses	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	5. Accrued expenses Accrued expenses consist of the following at December 31, 2015 and 2014: 2015 2014 Accrued executive severance $ 100,000 $ 100,000 Accrued audit and tax preparation 93,500 55,500 Accrued legal professional fees 76,500 111,600 Accrued outside services 58,813 - Accrued clinical study expenses 22,777 64,464 Accrued board of director's fees - 12,000 Accrued other 7,784 25,892 $ 359,374 $ 369,456 On November 6, 2012, the Company entered into a Severance and Advisory Agreement (the “Severance Agreement”) with Christopher M. Cashman in connection with his resignation as President and Chief Executive Officer, and a director of the Company. Pursuant to the Severance Agreement, Mr. Cashman will receive, as severance along with other non-cash items, six months of his base salary payable over the following six month period and bonus payments of $100,000 upon each of four bonus payment events tied to the Company’s clinical trial plan for the dermaPACE device, or December 31, 2016, whichever occurs first. The Company achieved three of the four bonus payment events in 2014 and paid $300,000 in accrued executive severance during the year ended December 31, 2014. The accrued executive severance at December 31, 2014 and 2015 represents the unpaid portion of the bonus payments.

Note 6 - Notes Payable, Related

Note 6 - Notes Payable, Related Parties	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
Debt Disclosure [Text Block]	6. Notes payable, related parties The notes payable, related parties were issued in conjunction with the Company’s purchase of the orthopedic division of HealthTronics, Inc. on August 1, 2005. The notes payable, related parties bear interest at 6% per annum. Quarterly interest through June 30, 2010, was accrued and added to the principal balance. Interest was paid quarterly in arrears beginning September 30, 2010. All remaining unpaid accrued interest and principal was due August 1, 2015. On June 15, 2015, the Company and HealthTronics, Inc. entered into an amendment (the “Note Amendment”) to amend certain provisions of the notes payable, related parties. The Note Amendment provides for the extension of the due date to January 31, 2017. I n connection with the Note Amendment, the Company entered into a security agreement with HealthTronics, Inc. to provide a first security interest in the assets of the Company. The notes payable, related parties bear interest at 8% per annum effective August 1, 2015 and during any period when an Event of Default occurs, the applicable interest rate shall increase by 2% per annum. The Company will be required to make mandatory prepayments of principal on the notes payable, related parties equal to 20% of the proceeds received by the Company through the issuance or sale of any equity securities in cash or through the licensing of the Company’s patents or other intellectual property rights. The notes payable, related parties had an aggregate outstanding principal balance of $5,348,112, net of $24,631 debt discount at December 31, 2015 and $5,372,743 at December 31, 2014, respectively. In addition, the Company, in connection with the Note Amendment, issued to HealthTronics, Inc. on June 15, 2015, an aggregate total of 3,310,000 warrants (the “Class K Warrants”) to purchase shares of the Company’s common stock, $0.001 par value (the “Common Stock”), at an exercise price of $0.55 per share, subject to certain anti-dilution protection. Each Class K Warrant represents the right to purchase one share of Common Stock. The warrants vested upon issuance and expire after ten years. Accrued interest currently payable totaled $239,803 and $81,864 at December 31, 2015 and 2014, respectively. Maturities on notes payable, related parties are as follows: Years ending December 31, Amount 2016 $ - 2017 5,372,743 Total $ 5,372,743 Interest expense on notes payable, related parties totaled $413,200 and $325,804 for the years ended December 31, 2015 and 2014, respectively.

Note 7 - Income Taxes

Note 7 - Income Taxes	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
Income Tax Disclosure [Text Block]	7. Income taxes The Company files income tax returns in the United States federal jurisdiction and various state and foreign jurisdictions. The Company is no longer subject to United States federal and state and non-United States income tax examinations by tax authorities for years before 2007. Deferred income taxes are provided for temporary differences between the carrying amounts and tax basis of assets and liabilities. Deferred taxes are classified as current or noncurrent based on the financial statement classification of the related asset or liability giving rise to the temporary difference. For those deferred tax assets or liabilities (such as the tax effect of the net operating loss carryforwards) which do not relate to a financial statement asset or liability, the classification is based on the expected reversal date of the temporary difference. The income tax provision (benefit) from continuing operations consists of the following at December 31, 2015 and 2014: 2015 2014 Current: Federal $ - $ - State - - Foreign - - - - Deferred: Federal (1,605,319 ) (2,198,311 ) State (176,377 ) (241,530 ) Foreign 2,419 9,532 Deferred Tax True Up 1,803,402 - Change in valuation allowance (24,125 ) 2,430,309 $ - $ - The income tax provision (benefit) amounts differ from the amounts computed by applying the United States federal statutory income tax rate of 35% to pretax income (loss) from continuing operations as a result of the following for the years ended December 31, 2015 and 2014: 2015 2014 Tax expense (benefit) at statutory rate $ (1,683,600 ) $ (2,090,928 ) Increase (reduction) in income taxes resulting from: State income taxes (benefit), net of federal benefit (119,778 ) (148,758 ) Non-deductible gain on warrant valuation adjustment (19,895 ) (156,011 ) Income from foreign subsidiaries 12,330 16,615 Deferred tax true up 1,803,402 - Change in valuation allowance - United States (24,125 ) 2,439,841 Other 31,666 (60,759 ) Income tax expense (benefit) $ - $ - The tax effects of temporary differences that give rise to the deferred tax assets at December 31, 2015 and 2014 are as follows: 2015 2014 Deferred tax assets: Net operating loss carryforwards $ 26,451,449 $ 24,919,846 Net operating loss carryforwards - foreign 127,578 129,997 Excess of tax basis over book value of property and equipment 20,158 20,685 Excess of tax basis over book value of intangible assets 443,597 439,569 Stock-based compensation 1,834,172 3,447,183 Accrued employee compensation 90,442 37,736 Captialized equity costs 75,471 75,471 Inventory reserve 35,156 31,661 29,078,023 29,102,148 Valuation allowance (29,078,023 ) (29,102,148 ) Net deferred tax assets $ - $ - During 2015, the Company undertook a detailed review of the Company's deferred taxes and it was determined that some reclassifications and adjustments were needed for stock-based compensation. All adjustments were offset by changes to the Company's valuation allowance and have been reflected in the 2015 year end balances noted above. The Company’s ability to use its net operating loss carryforwards could be limited and subject to annual limitations. In connection with future offerings, the Company may realize a “more than 50% change in ownership” which could further limit its ability to use its net operating loss carryforwards accumulated to date to reduce future taxable income and tax liabilities. Additionally, because United States tax laws limit the time during which net operating loss carryforwards may be applied against future taxable income and tax liabilities, the Company may not be able to take advantage of all or portions of its net operating loss carryforwards for federal income tax purposes. The federal net operating loss carryforwards at December 31, 2015 will expire as follows: Years ending December 31, Amount 2025 $ 1,376,740 2026 7,291,084 2027 12,280,771 2028 6,922,963 2029 4,816,700 2030 7,667,557 2031 8,816,976 2032 4,768,716 2033 5,413,661 2034 6,663,638 2035 4,077,996 Total $ 70,096,802

Note 8 - Equity Transactions

Note 8 - Equity Transactions	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	8. Equity Transactions 2014 Private Placement On March 17, 2014, in conjunction with a private placement of securities (the “2014 Private Placement”) with institutional and select accredited investors, the Company issued an aggregate total of 6,210,000 shares of common stock and 6,175 shares of preferred stock (the “Series A Convertible Preferred Stock”) for an aggregate total purchase price of $9,280,000. Each share of Series A Convertible Preferred Stock is convertible into 2,000 shares of common stock at the option of the holder. The proceeds received by the Company were $8,562,500, net of offering costs of $717,500. The Company, in connection with the 2014 Private Placement, issued to the investors an aggregate total of 23,200,000 warrants (the “Series A Warrants”) to purchase shares of common stock at an exercise price of $0.50 per share. Each Series A Warrant represents the right to purchase one share of common stock. The warrants vested upon issuance and expire after five years. In addition, the Company, in connection with the 2014 Private Placement, issued to the investors an aggregate total of 13,920,000 warrants (the “Series B Warrants”) to purchase shares of common stock at an exercise price of $1.50 per share. Each Series B Warrant represents the right to purchase one share of common stock. The warrants vested upon issuance and expire after one year. Pursuant to the terms of a registration rights agreement that the Company entered with the investors in connection with the 2014 Private Placement, the Company filed a registration statement with the SEC in April 2014 that covers the shares of common stock and the shares of common stock issuable upon conversion of the Series A Convertible Preferred Stock and exercise of the Series A Warrants and Series B Warrants issued to the investors in the 2014 Private Placement. The registration statement was declared effective by the SEC on May 6, 2014. Kevin A. Richardson, II, chairman of the board of directors of the Company and now Acting Chief Executive Officer; Joseph Chiarelli, the former Chief Executive Officer of the Company; and, Michael N. Nemelka, the brother of a member of the Company’s board of directors and an existing shareholder of the Company, were purchasers in the 2014 Private Placement of $50,000, $40,000 and $50,000, respectively. At the closing of the 2014 Private Placement, the Company paid Newport Coast Securities, Inc., the placement agent for the private placement, and Oppenheimer & Co. Inc., the former placement agent, cash compensation based on the gross proceeds of the private placement and 696,000 Series A Warrants and 417,600 Series B Warrants. 18% Convertible Promissory Notes During the period January 24, 2014 through March 7, 2014, the Company entered into subscriptions payable for 18% convertible promissory notes, as amended, (the “18% Convertible Promissory Notes”) from selected accredited investors. Up to $1,000,000 aggregate principal amount of 18% Convertible Promissory Notes were offered by the Company. The Company completed the offering and issued an aggregate $815,000 in convertible notes in March 2014. Michael N. Nemelka, the brother of a member of the Company’s board of directors and an existing shareholder of the Company, purchased $110,000 of the convertible notes. The 18% Convertible Promissory Notes had a nine month term from the subscription date and the note holders could convert into Company common stock at anytime during the term at $0.55 per share. Upon the consummation of a qualified financing, as defined in the convertible note agreements, of $1,000,000 or more by the Company, the principal and interest on the 18% Convertible Promissory Notes would convert into Company common stock equal to the lower of (i) the Company common stock issued in the qualified financing, and (ii) $0.55 per share. The note holders would also receive, if any were issued, warrants or any other security issued in a qualified financing on similar terms to the qualified financing. The 18% Convertible Promissory Notes were unsecured. The 2014 Private Placement was a qualified financing as defined in the 18% Convertible Promissory Notes. As such, on March 17, 2014, in conjunction with the 2014 Private Placement discussed above, the 18% Convertible Promissory Notes, with an aggregate outstanding principal and accrued interest balance of $822,168, were automatically converted and the holders received in the aggregate 1,644,337 shares of common stock, 2,055,421 Series A Warrants, and 1,233,252 Series B Warrants. Subscription agreement On November 27, 2012, the Company and David N. Nemelka (the “Subscriber”), the brother of a member of the Company’s board of directors, entered into a subscription agreement (the “Subscription Agreement”) whereby the Subscriber agreed to purchase from the Company, and the Company agreed to sell and issue, a total of 4,000,000 shares of the Company’s unregistered common stock at a purchase price equal to $0.25 per share, for an aggregate sales price of $1,000,000 (the “Purchase Price”). The shares are subject to piggy-back registration rights if the Company files a registration statement for an offering of securities. The Purchase Price was payable to the Company as follows: (i) $50,000 on or before January 31, 2013; (ii) $50,000 on or before February 15, 2013; and (iii) the balance of $900,000 on or before May 27, 2014 (the “Outside Due Date”). The Subscriber could make payments of the Purchase Price at his discretion in minimum installments of $100,000 each, until the Outside Due Date. In the event that at any time after February 15, 2013, the Company’s total available cash should be less than $100,000, the Subscriber would, upon demand of the Company, pay to the Company $100,000 of the then outstanding balance of the Purchase Price, which payment would be due within 30 days of the demand. There was no limit on the number of demands that the Company could make pursuant to this provision of the Subscription Agreement, provided, however, that in no event could the Company provide more than one notice of demand for payment in any 30 day period. On May 27, 2014, the Subscriber paid the Company the remaining $900,000 and was issued 3,600,000 shares of unregistered common stock of the Company as full settlement of the Subscription Agreement. $278,500 Convertible Promissory Note and Warrants On February 10, 2014, the Company entered into a financing transaction with an accredited investor for the sale of an 8% convertible promissory note (the “$278,500 Convertible Note”) and warrants (the “Class J Warrants”) in the principal amount of $278,500, with gross proceeds of $250,000 to the Company after payment of a 10% original issue discount and related professional expenses. The $278,500 Convertible Note and Class J Warrants were issued pursuant to the terms of a purchase agreement among the Company and the holder. The convertible note was an unsecured obligation of the Company and, unless earlier redeemed, matured on August 11, 2014. The convertible note accrued interest at the rate of 8% per annum and included a 10%, or $25,000, original issuance discount. The Company had the right to prepay the convertible note and accrued interest during the first 180 days following the date of issuance. During that time, the amount of any prepayment during the first 60 days was 120% of the outstanding amounts owed, and the amount of the prepayment increased every subsequent 30 days. The $278,500 Convertible Note was convertible, after the first 180 days, in whole or in part, at the option of the investor, into shares of Company common stock at a conversion price of the lower of 75% of the lowest reported sale price of the Company’s common stock for the 20 trading days immediately prior to (i) the closing date of the financing, or (ii) 75% of the lowest reported sale price for the 20 days prior the conversion date of the convertible note. The convertible note included full ratchet anti-dilution protection for any lower priced issuances of common stock or securities convertible or exchangeable into Company common stock. The Class J Warrants entitle the holder to purchase, in the aggregate, 629,378 shares of the Company’s common stock. The Warrants were exercisable upon the six month anniversary of the closing date (August 10, 2014) and expire five years from the closing date. The Class J Warrants have an exercise price equal to $0.4425. The Class J Warrants may be exercised for cash or on a cashless basis. The exercise price of the warrants is subject to adjustment for stock splits, combinations or similar events, and, in this event, the number of shares issuable upon the exercise of the warrant will also be adjusted so that the aggregate exercise price shall be the same immediately before and immediately after the adjustment. In addition, the exercise price is also subject to a “full ratchet” anti-dilution adjustment if the Company issues or is deemed to have issued securities at a price lower than the then applicable exercise price. In March 2014, the Company repaid the $278,500 Convertible Note in full, which totaled $337,171 with accrued interest and a prepayment penalty of $56,195. $128,500 Convertible Promissory Note On December 23, 2013, the Company entered into a financing transaction with an accredited investor for the sale of an 8% convertible promissory note (the “$128,500 Convertible Note”) in the principal amount of $128,500, with gross proceeds of $125,000 to the Company after payment of related professional expenses. The $128,500 Convertible Note was issued pursuant to the terms of a purchase agreement among the Company and the accredited investor. The convertible note was an unsecured obligation of the Company and, unless earlier redeemed, matured on September 26, 2014. The convertible note accrued interest at the rate of 8% per annum. The Company had the right to prepay the convertible note and accrued interest during the first 180 days following the date of issuance. During that time, the amount of any prepayment during the first 30 days was 115% of the outstanding amounts owed, and the amount of the prepayment increased every subsequent 30 days. The $128,500 Convertible Note was convertible, after the first 180 days, in whole or in part, at the option of the investor, into shares of Company common stock at a conversion price of 61% of the lowest three reported sale prices of the Company’s common stock for the 10 trading days immediately prior to the conversion date. The convertible note included full ratchet anti-dilution protection for any lower priced issuances of common stock or securities convertible or exchangeable into Company common stock. In March 2014, the Company repaid the $128,500 Convertible Note in full, which totaled $158,055, with accrued interest and prepayment penalty of $29,555. $78,500 Convertible Promissory Note On February 18, 2014, the Company entered into a second tranche of financing with the accredited investor for the $128,500 Convertible Note for the sale of an 8% Convertible Promissory Note (the “$78,500 Convertible Note”) under the same terms as the first tranche in the principal amount of $78,500, with gross proceeds of $75,000 to the Company after payment of related professional expenses. The $78,500 Convertible Note was issued pursuant to the terms of a purchase agreement among the Company and the accredited investor. The convertible note was an unsecured obligation of the Company and, unless earlier redeemed, matured on November 20, 2014. The convertible note accrued interest at the rate of 8% per annum. The Company had the right to prepay the convertible note and accrued interest during the first 180 days following the date of issuance. During that time, the amount of any prepayment during the first 30 days was 115% of the outstanding amounts owed, and the amount of the prepayment increased every subsequent 30 days. The $78,500 Convertible Note was convertible, after the first 180 days, in whole or in part, at the option of the investor, into shares of Company common stock at a conversion price of 61% of the lowest three reported sale prices of the Company’s common stock for the 10 trading days immediately prior to the conversion date. The convertible note included full ratchet anti-dilution protection for any lower priced issuances of common stock or securities convertible or exchangeable into Company common stock. In March 2014, the Company repaid the $78,500 Convertible Note in full, which totaled $90,275 with accrued interest and prepayment penalty of $11,775. Consulting Agreements In February 2014, the Company renewed one consulting contract and entered into three additional consulting agreements for which a portion of the fee for the services performed was paid with Company common stock. The Company issued 1,005,000 shares of common stock under these agreements in February 2014 through May 2014. The fair value of the common stock of $624,150 issued to the consultants, based upon the closing market price of the Company’s common stock at the dates the common stock was issued, was recorded as a non-cash general and administrative expense for the year ended December 31, 2014.

Note 9 - Preferred Stock

Note 9 - Preferred Stock	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
Preferred Stock [Text Block]	9 . Preferred Stock The Company’s Articles of Incorporation authorize the issuance of up to 5,000,000 shares of “blank check” preferred stock with designations, rights and preferences as may be determined from time to time by the board of directors. On March 14, 2014, the Company filed a Certificate of Designation of Preferences, Rights and Limitations for Series A Convertible Preferred Stock of the Company (the “Certificate of Designation”) with the Nevada Secretary of State. The Certificate of Designation amends the Company’s Articles of Incorporation to designate 6,175 shares of preferred stock, par value $0.001 per share, as Series A Convertible Preferred Stock. The Series A Convertible Preferred Stock has a stated value of $1,000 per share. On March 17, 2014, in connection with the 2014 Private Placement, the Company issued 6,175 shares of Series A Convertible Preferred Stock (for a more detailed discussion regarding the 2014 Private Placement, see Note 8). Under the Certificate of Designation, holders of Series A Convertible Preferred Stock are entitled to receive dividends equal (on an as-if-converted-to-common-stock basis) to and in the same form as dividends (other than dividends in the form of common stock) actually paid on shares of the common stock when, as and if such dividends are paid. Such holders will participate on an equal basis per-share with holders of common stock in any distribution upon winding up, dissolution, or liquidation of the Company. Holders of Series A Convertible Preferred Stock are entitled to convert each share of Series A Convertible Preferred Stock into 2,000 shares of common stock, provided that after giving effect to such conversion, such holder, together with its affiliates, shall not beneficially own in excess of 9.99% of the number of shares of common stock outstanding (the “Beneficial Ownership Limitation”). Holders of the Series A Convertible Preferred Stock are entitled to vote on all matters affecting the holders of the common stock on an “as converted” basis, provided that such holder shall only vote such shares of Series A Convertible Preferred Stock eligible for conversion without exceeding the Beneficial Ownership Limitation. In November and December 2014, the holders of Series A Convertible Preferred Stock converted 5,010 shares of Series A Convertible Preferred Stock into 10,020,000 shares of common stock. On January 6, 2015, the holders of Series A Convertible Preferred Stock converted the remaining 1,165 shares of Series A Convertible Preferred Stock into 2,330,000 shares of common stock. As of January 6, 2015, there were no more outstanding shares of Series A Convertible Preferred Stock.

Note 10 - Warrants

Note 10 - Warrants	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
Warrants [Text Block]	10 . Warrants A summary of warrants as of December 31, 2015 and 2014, and the changes during the years ended December 31, 2015 and 2014, is presented as follows: Warrant class Outstanding as of December 31, 2013 Issued Exercised Expired Outstanding as of December 31, 2014 Issued Exercised Expired Outstanding as of December 31, 2015 Class A Warrants 1,106,627 - - (1,106,627 ) - - - - - Class B Warrants 1,106,627 - - (1,106,627 ) - - - - - Class E Warrants 3,576,737 - - - 3,576,737 - - - 3,576,737 Class F Warrants 300,000 - - - 300,000 - - - 300,000 Class G Warrants 1,503,409 - - - 1,503,409 - - - 1,503,409 Class H Warrants 1,988,095 - - - 1,988,095 - - - 1,988,095 Class I Warrants 1,043,646 - - - 1,043,646 - - - 1,043,646 Class J Warrants - 629,378 - - 629,378 - - - 629,378 Class K Warrants - - - - - 3,310,000 - - 3,310,000 Series A Warrants - 25,951,421 - - 25,951,421 - - - 25,951,421 Series B Warrants - 15,570,852 - - 15,570,852 - - (15,570,852 ) - 10,625,141 42,151,651 - (2,213,254 ) 50,563,538 3,310,000 - (15,570,852 ) 38,302,686 A summary of the warrant exercise price per share and expiration date is presented as follows: Exercise Expiration price/share date Class A Warrants $ 4.00 September 2014 Class B Warrants $ 8.00 September 2014 Class E Warrants $ 4.00 April 2016 Class F Warrants $ 0.35 February 2018 Class G Warrants $ 0.80 July 2018 Class H Warrants $ 0.80 July 2018 Class I Warrants $ 0.85 September 2018 Class J Warrants $ 0.44 February 2019 Class K Warrants $ 0.55 June 2025 Series A Warrants $ 0.50 March 2019 Series B Warrants $ 1.50 March 2015 The exercise price and the number of shares covered by the warrants will be adjusted if the Company has a stock split, if there is a recapitalization of the Company’s common stock, or if the Company consolidates with or merges into another company. The exercise price of the Class J Warrants, Class K Warrants, the Series A Warrants and the Series B Warrants are subject to a “down-round” anti-dilution adjustment if the Company issues or is deemed to have issued securities at a price lower than the then applicable exercise price of the warrants. The Class J Warrants and Class K Warrants may be exercised on a physical settlement or on a cashless basis. The Series A Warrants and Series B Warrants may be exercised on a physical settlement basis if a registration statement underlying the warrants if effective. If a registration statement is not effective (or the prospectus contained therein is not available for use) for the resale by the holder of the Series A Warrants or Series B Warrants, then the holder may exercise the warrants on a cashless basis. The Series B Warrants expired in March 2015. In February 2013, the Company issued 2,000,000 warrants to a consultant to purchase the Company’s common stock at $0.35 per share (the “Class F Warrants”). The five year Class F Warrants vest 300,000 on the date of grant and 1,700,000 upon the completion of a $5,000,000, or greater, capital raise on or prior to June 8, 2013. A capital raise was not completed for the requisite amount and the 1,700,000 Class F Warrants expired by their terms. The Company recorded the underlying cost of the 300,000 Class F Warrants as a cost of the Public Offering. In June 2015, the Company, in connection with the Note Amendment (Note 7), issued to HealthTronics, Inc. an aggregate total of 3,310,000 Class K Warrants to purchase shares of the Company’s common stock, $0.001 par value, at an exercise price of $0.55 per share, subject to certain anti-dilution protection. Each Class K Warrant represents the right to purchase one share of Common Stock. The warrants vested upon issuance and expire after ten years. The Class J Warrants, the Class K Warrants, the Series A Warrants and the Series B Warrants are derivative financial instruments. The estimated fair value of the Class J Warrants at the date of grant was $12,776. The related debt discount was accreted to interest expense through the maturity date of the related note. The estimated fair value of the Class K Warrants at the date of grant was $36,989 and recorded as debt discount, which is accreted to interest expense through the maturity date of the related notes payable, related parties. The estimated fair values of the Series A Warrants and the Series B Warrants at the date of grant were $557,733 for the warrants issued in conjunction with the 2014 Private Placement and $47,974 for the warrants issued in conjunction with the 18% Convertible Promissory Notes. The fair value of the Series A Warrants and Series B Warrants were recorded as equity issuance costs in 2014, a reduction of additional paid-in capital. Prior to the fourth quarter of 2014, these warrants were not treated as derivative financial instruments and recorded at fair value. Accordingly, during the fourth quarter 2014, we recorded an adjustment to reduce interest expense by $327,088 and reflect a gain on the fair value adjustment for the warrants of $458,857 to reflect the annual activity for these instruments. The amounts were not significant to any of the previously reported quarterly condensed consolidated financial statements. The Series B Warrants expired unexercised in March 2015. The estimated fair values were determined using a binomial option pricing model based on various assumptions. The Company’s derivative liabilities are adjusted to reflect estimated fair value at each period end, with any decrease or increase in the estimated fair value being recorded in other income or expense accordingly, as adjustments to the fair value of derivative liabilities. Various factors are considered in the pricing models the Company uses to value the warrants, including the Company’s current common stock price, the remaining life of the warrants and the volatility of the Company’s common stock price.

Note 11 - Commitments and Conti

Note 11 - Commitments and Contingencies	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	11 . Commitments and contingencies Operating Leases The Company leases office and storage space. Rent expense for the years ended December 31, 2015 and 2014, was $155,926 and $132,814, respectively. The Company amended the lease on November 1, 2015 to remain in the current space on a month-to-month basis. Litigation The Company is involved in various legal matters that have arisen in the ordinary course of business. While the ultimate outcome of these matters is not presently determinable, it is the opinion of management that the resolution will not have a material adverse effect on the financial position or results of operations of the Company.

Note 12 - Stock-based Compensat

Note 12 - Stock-based Compensation	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	12 . Stock-based compensation On November 1, 2010, the Company approved the Amended and Restated 2006 Stock Incentive Plan of SANUWAVE Health, Inc. effective as of January 1, 2010 (the “Stock Incentive Plan”). The Stock Incentive Plan permits grants of awards to selected employees, directors and advisors of the Company in the form of restricted stock or options to purchase shares of common stock. Options granted may include non-statutory options as well as qualified incentive stock options. The Stock Incentive Plan is currently administered by the board of directors of the Company. The Stock Incentive Plan gives broad powers to the board of directors of the Company to administer and interpret the particular form and conditions of each option. The stock options granted under the Stock Incentive Plan are non-statutory options which generally vest over a period of up to three years and have a ten year term. The options are granted at an exercise price determined by the board of directors of the Company to be the fair market value of the common stock on the date of the grant. At December 31, 2015 and 2014 the Stock Incentive Plan reserved a total of 12,500,000 and 8,500,000, respectively, shares of common stock for grant. On October 1, 2015, the Company granted to the active employees and members of the board of directors options to purchase 1,900,000 shares of common stock at an exercise price of $0.11 per share and vested upon issuance. Using the Black-Scholes option pricing model, management has determined that the options had a fair value per share of $0.11 resulting in compensation expense of $209,000. Compensation cost was recognized upon grant. On October 1, 2015, the Company granted to the active employees, members of the board of directors and members of the Medical Advisory Board options to purchase 1,450,000 shares of common stock an exercise price of $0.50 per share and vested upon issuance. Using the Black-Scholes option pricing model, management has determined that the options had a fair value per share of $0.10 resulting in compensation expense of $145,000. Compensation cost was recognized upon grant. On August 13, 2015, Mr. Chiarelli and the Company entered into a confidential settlement agreement in response to an action filed against the Company by Mr. Chiarelli. The settlement agreement contains the entire understanding and complete agreement of the parties involved with respect to the circumstances, matters, events and transactions that were a subject of the action. A part of the settlement was the issuance of stock options. Using the Black-Scholes option pricing model, management has determined that the options had a fair value resulting in compensation expense of $98,100. Compensation cost was recognized upon grant. On April 28, 2015, the Company granted two members of the Company’s Medical Advisory Board each options to purchase 50,000 shares of the Company’s common stock at an exercise price of $0.55 per share in place of an annual cash consulting fee for calendar year 2015. Using the Black-Scholes option pricing model, management has determined that the options had a fair value per share of $0.11 resulting in compensation expense of $11,107. Compensation cost was recognized over the requisite service period in calendar year 2015. On September 4, 2014, the Company granted two members of the Company’s Medical Advisory Board each options to purchase 75,000 shares of the Company’s common stock at an exercise price of $0.55 per share in place of an annual cash consulting fee for calendar year 2014. Using the Black-Scholes option pricing model, management has determined that the options had a fair value per share of $0.24 resulting in compensation expense of $35,625. Compensation cost was recognized over the requisite service period in calendar year 2014. On May 7, 2014, the Company granted to the active employees options to purchase 900,000 shares of common stock at an exercise price of $0.55 per share. Using the Black-Scholes option pricing model, management has determined that the options had a fair value per share of $0.48 resulting in compensation expense of $429,001. Compensation cost is being recognized over the requisite service period. The fair value of each option award is estimated on the date of grant using the Black-Scholes option pricing model using the following weighted average assumptions for the years ended December 31, 2015 and 2014: 2015 2014 Weighted average expected life in years 5.0 5.4 Weighted average risk free interest rate 1.42 % 1.81 % Weighted average volatility 120.63 % 136.11 % Forfeiture rate 0.0 % 0.0 % Expected dividend yield 0.0 % 0.0 % The expected life of options granted represent the period of time that options granted are expected to be outstanding and are derived from the contractual terms of the options granted. The risk-free rate for periods within the contractual life of the option is based on the United States Treasury yield curve in effect at the time of the grant. Since there is a limited trading history for our common stock, the expected volatility is based on historical data from companies similar in size and value to us. We estimate pre-vesting forfeitures at the time of grant and revise those estimates in subsequent periods if actual forfeitures differ from those estimates. The expected dividend yield is based on our historical dividend experience, however, since our inception, we have not declared dividends. The amount of stock-based compensation expense recognized during a period is based on the portion of the awards that are ultimately expected to vest. Ultimately, the total expense recognized over the vesting period will equal the fair value of the awards that actually vest. For the years ended December 31, 2015 and 2014, the Company recognized $504,534 and $135,015, respectively, as compensation cost related to options granted. The remaining compensation cost will be recognized as follows: Unrecognized Compensation Years ending December 31, Cost 2016 $ 6,000 Total $ 6,000 A summary of option activity as of December 31, 2015 and 2014, and the changes during the years ended December 31, 2015 and 2014, is presented as follows: Weighted Average Exercise Price Options per share Outstanding at December 31, 2013 8,366,830 $ 1.17 Granted 1,050,000 $ 0.55 Exercised (60,000 ) $ 0.21 Cancelled - $ - Forfeited or expired (2,150,000 ) $ 0.41 Outstanding at December 31, 2014 7,206,830 $ 1.31 Granted 4,950,000 $ 0.35 Exercised - $ - Cancelled - $ - Forfeited or expired (2,083,445 ) $ 2.39 Outstanding at December 31, 2015 10,073,385 $ 0.62 Vested and exercisable at December 31, 2015 9,898,383 $ 0.62 The range of exercise prices for options was $0.11 to $2.00 for options outstanding at December 31, 2015 and 2014. The aggregate intrinsic value for outstanding options was $0 at December 31, 2015 and 2014. The aggregate intrinsic value for all vested and exercisable options was $0 at December 31, 2015 and 2014. The weighted average remaining contractual term for outstanding exercisable stock options is 7.46 years and 6.43 years as of December 31, 2015 and 2014, respectively. A summary of the Company’s nonvested options as of December 31, 2015 and 2014, and changes during the years ended December 31, 2015 and 2014, is presented as follows: Weighted Average Exercise Price Options per share Outstanding at December 31, 2013 3,254,092 $ 0.35 Granted 1,050,000 $ 0.55 Vested (1,464,551 ) $ 0.41 Cancelled - $ - Forfeited or expired (1,924,999 ) $ 0.39 Outstanding at December 31, 2014 914,542 $ 0.37 Granted 4,950,000 $ 0.35 Vested (5,672,874 ) $ 0.36 Cancelled - $ - Forfeited or expired (16,666 ) $ 0.55 Outstanding at December 31, 2015 175,002 $ 0.36

Note 13 - Changes in Other Comp

Note 13 - Changes in Other Comprehensive Income (Loss)	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
Comprehensive Income (Loss) Note [Text Block]	13. Changes in other comprehensive income (loss) A summary of the amounts recognized in other comprehensive income (loss) as of December 31, 2015 and 2014, and changes during the years then ended, is presented as follows: Currency Translations Total Balance, at December 31, 2013 $ 6,688 $ 6,688 Net change in other comprehensive loss (19,165 ) (19,165 ) Balance, at December 31, 2014 (12,477 ) (12,477 ) Net change in other comprehensive loss (20,685 ) (20,685 ) Balance, at December 31, 2015 $ (33,162 ) $ (33,162 )

Note 14 - Segment and Geographi

Note 14 - Segment and Geographic Information	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	14. Segment and geographic information The Company has one line of business with revenues being generated from sales in Europe, Canada, Asia and Asia/Pacific. All significant expenses are generated in the United States. All significant assets are located in the United States.

Note 15 - Subsequent Events

Note 15 - Subsequent Events	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
Subsequent Events [Text Block]	15. Subsequent event s 2016 Equity Offering On March 11, 2016, in conjunction with an equity offering of securities (the “2016 Equity Offering”) with select accredited investors, the Company issued an aggregate of 25,495,835 shares of common stock for an aggregate purchase price of $1,529,750. The mandatory prepayment of principal on the notes payable, related parties equal to 20% of the proceeds received by the Company has been waived by HealthTronics, Inc. for this 2016 Equity Offering. The Company, in connection with the 2016 Equity Offering, issued to the investors an aggregate of 25,495,835 warrants (the “Class L Warrants”) to purchase shares of common stock at an exercise price of $0.08 per share. Each Class L Warrant represents the right to purchase one share of Common Stock. The warrants vested upon issuance and expire on March 17, 2019. Pursuant to the terms of a Registration Rights Agreement that the Company entered with the investors in connection with the 2016 Equity Offering, the Company is required to file a registration statement that covers the shares of common stock and the shares of common stock issuable upon exercise of the Class L Warrants. The failure on the part of the Company to satisfy certain deadlines described in the Registration Rights Agreement may subject the Company to payment of certain monetary penalties. Michael N. Nemelka, the brother of a member of the Company’s board of directors and an existing shareholder of the Company, was a purchaser in the 2016 Equity Offering of $100,000. $58,300 Convertible Promissory Note s and Warrants On February 1, 2016, the Company entered into a financing transaction for the sale of an 8% Convertible Promissory Note (the “$58,300 Convertible Note”) and warrants (the “Class M Warrants”) in the principal amount of $58,300 each, with gross proceeds of $50,000 to the Company after payment of a 10% original issue discount and related professional expenses. The offering was conducted pursuant to the exemption from registration provided by Section 4(a)(2) of the Act and Rule 506 of Regulation D thereunder. The Company did not utilize any form of general solicitation or general advertising in connection with the offering. The $58,300 Convertible Note was offered and sold to two accredited investors. The $58,300 Convertible Note and Class M Warrants were issued pursuant to the terms of a purchase agreement among the Company and the Investors. The convertible note is an unsecured obligation of the Company and, unless earlier redeemed, matures on August 1, 2016. The Company has the right to prepay the convertible note and accrued interest during the first sixty (60) days following the date of issuance. During that time, the amount of any prepayment during the first sixty (60) days is 120% of the outstanding amounts owed, and the amount of the prepayment increases every subsequent thirty (30) days. Each Class M Warrant represents the right to purchase one share of Common Stock. The warrants vested upon issuance and expire February 21, 2021. The $58,300 Convertible Note is convertible, at any time from the issuance date, in whole or in part, at the option of the investor, into shares of Company common stock at a conversion price of 30% of the lowest reported sale price of the Company’s common stock for the 20 trading days immediately prior to (i) the date of the purchase agreement or (ii) the voluntary conversion date. The Company is evaluating the accounting for the Convertible Note. Series A Warrant Conversion On January 13, 2016, the Company entered into an Exchange Agreement (the “Exchange Agreement”) with certain beneficial owners (the “Investors”) of Series A warrants (the “Warrants”) to purchase shares of the Company’s common stock, $0.001 par value per share (the “Common Stock”), pursuant to which the Investors exchanged (the “Exchange”) all of their respective Warrants for either (i) shares of Common Stock or (ii) shares of Common Stock and shares of the Company’s Series B Convertible Preferred Stock, $0.001 par value (the “Preferred Stock”). The Exchange was based on the following exchange ratio (the “Exchange Ratio”): 1 Series A Warrant = 0.4685 shares of capital stock. Investors who, as a result of the Exchange, owned in excess of 9.99% (the “Ownership Threshold”) of the outstanding Common Stock, received a mixture of Common Stock and shares of Preferred Stock. They received Common Stock up to the Ownership Threshold, and received shares of Preferred Stock beyond the Ownership Threshold (but the total shares of Common Stock and Preferred Stock issued to such holders was still based on the same Exchange Ratio). The relative rights, preferences, privileges and limitations of the Preferred Stock are as set forth in the Company’s Certificate of Designation of Series B Convertible Preferred Stock, which was filed with the Secretary of State of the State of Nevada on January 12, 2016 (the “Series B Certificate of Designation”). In the Exchange an aggregate number of 23,701,428 Warrants were exchanged for 7,447,954 shares of Common Stock and 293 shares of Preferred Stock. Pursuant to the Series B Certificate of Designation, each of the Preferred Stock shares is convertible into shares of Common Stock at an initial rate of 1 Preferred Stock share for 12,500 Common Stock shares, which conversion rate is subject to further adjustment as set forth in the Series B Certificate of Designation. Pursuant to the terms of the Series B Certificate of Designation, the holders of the Preferred Stock shares will generally be entitled to that number of votes as is equal to the number of shares of Common Stock into which the Preferred Stock may be converted as of the record date of such vote or consent, subject to the Beneficial Ownership Limitation. In connection with entering into the Exchange Agreement, the Company also entered into a Registration Rights Agreement, dated January 13, 2016, with the Investors. The Registration Rights Agreement requires that the Company file with the SEC a registration statement to register for resale the shares of the Common Stock issued in connection with the Exchange and the Common Stock issuable upon conversion of the Preferred Stock shares (the “Preferred Stock Conversion Shares”).

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Foreign currency translation Foreign Currency Matters
Consolidation, Policy [Policy Text Block]	Principles of consolidation
Use of Estimates, Policy [Policy Text Block]	Estimates
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and cash equivalents
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentration of credit risk and limited suppliers We depend on suppliers for product component materials and other components that are subject to stringent regulatory requirements. We currently purchase most of our product component materials from single suppliers and the loss of any of these suppliers could result in a disruption in our production. If this were to occur, it may be difficult to arrange a replacement supplier because certain of these materials may only be available from one or a limited number of sources. In addition, establishing additional or replacement suppliers for these materials may take a substantial period of time, as certain of these suppliers must be approved by regulatory authorities.
Receivables, Policy [Policy Text Block]	Accounts receivable
Inventory, Policy [Policy Text Block]	Inventory The Company analyzes its inventory levels and writes down inventory that has, or is expected to, become obsolete.
Property, Plant and Equipment, Policy [Policy Text Block]	Depreciation of property and equipment
Goodwill and Intangible Assets, Policy [Policy Text Block]	Intangible assets T he Company regularly reviews intangible assets to determine if facts and circumstances indicate that the useful life is shorter than the Company originally estimated or that the carrying amount of the assets may not be recoverable. Factors the Company considers important and could trigger an impairment review include the following: ? Significant delays or obstacles encountered in the dermaPACE device clinical trial and PMA application; ? Significant changes in the manner in which the Company uses its assets or significant changes in the Company’s overall business strategy; and ? Significant underperformance of the Company’s assets relative to future operating results. If such facts and circumstances exist, the Company assesses the recoverability of the intangible assets by comparing the projected undiscounted net cash flows associated with the related asset or group of assets over their remaining lives against their respective carrying amounts. If recognition of an impairment charge is necessary, it is measured as the amount by which the carrying amount of the intangible asset exceeds its fair value.
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair value of financial instruments The Company has adopted ASC 820-10, Fair Value Measurements The ASC 820-10 hierarchy ranks the quality and reliability of inputs, or assumptions, used in the determination of fair value and requires financial assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories: Level 1 - Observable inputs that reflect quoted prices (unadjusted) in active markets for identical assets and liabilities; Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly; and Level 3 - Unobservable inputs that are not corroborated by market data, therefore requiring the Company to develop its own assumptions. The following table sets forth a summary of changes in the fair value of the derivative liability for the year ended December 31, 2015: Warrant Liability Balance at December 31, 2014 $ 159,626 New issuances 36,989 Change in fair value (58,515 ) Balance at December 31, 2015 $ 138,100 The Company accounts for derivative instruments under ASC 815, Accounting for Derivative Instruments and Hedging Activities The Company’s notes payable, related parties had an aggregate outstanding principal balance of $5,348,112, net of $24,631 debt discount at December 31, 2015 and $5,372,743 at December 31, 2014, respectively. Interest accrues on the notes at a rate of eight percent per annum, effective June 15, 2015. The fair value was determined using estimated future cash flows discounted at current rates, which is a Level 3 measurement. The estimated fair value of the Company’s notes payable, related parties was $4,844,792 and $5,221,985 at December 31, 2015 and 2014, respectively.
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Impairment of long-lived assets
Revenue Recognition, Policy [Policy Text Block]	Revenue recognition
Shipping and Handling Cost, Policy [Policy Text Block]	Shipping and handling costs
Income Tax, Policy [Policy Text Block]	I ncome taxes Income Taxes . Deferred tax assets and liabilities are determined based on differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is provided for the deferred tax assets, including loss carryforwards, when it is more likely than not that some portion or all of a deferred tax asset will not be realized. A provision of ASC 740, Income Taxes The Company will recognize in income tax expense interest and penalties related to income tax matters. For the years ended December 31, 2015 and 2014, the Company did not have any amounts recorded for interest and penalties.
Earnings Per Share, Policy [Policy Text Block]	Loss per share Earnings Per Share To the extent that securities are “anti-dilutive,” they are excluded from the calculation of diluted net income (loss) per share. As a result of the net loss for the years ended December 31, 2015 and 2014, respectively, all potentially dilutive shares were anti-dilutive and therefore excluded from the computation of diluted net loss per share. The anti-dilutive equity securities totaled 48,376,071 shares and 60,100,368 shares at December 31, 2015 and 2014, respectively.
Comprehensive Income, Policy [Policy Text Block]	Comprehensive income Comprehensive Income
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Stock-based compensation Compensation – Stock Compensation
Research and Development Expense, Policy [Policy Text Block]	Research and d evelopment
New Accounting Pronouncements, Policy [Policy Text Block]	Recent pronouncements In May 2014, the FASB issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers Revenue from Contracts with Customers (Topic 606) In April 2015, the FASB issued ASU 2015-03, Interest-Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs In July 2015, the FASB issued Accounting Standards Update No. 2015-11, Simplifying the Measurement of Inventory In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842)

Note 2 - Summary of Significa25

Note 2 - Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2015
Notes Tables
Schedule of Derivative Liabilities at Fair Value [Table Text Block]	Warrant Liability Balance at December 31, 2014 $ 159,626 New issuances 36,989 Change in fair value (58,515 ) Balance at December 31, 2015 $ 138,100

Note 3 - Inventory (Tables)

Note 3 - Inventory (Tables)	12 Months Ended
	Dec. 31, 2015
Notes Tables
Schedule of Inventory, Current [Table Text Block]	2015 2014 Inventory - finished goods $ 290,623 $ 263,027 Inventory - parts 87,450 92,744 Gross inventory 378,073 355,771 Provision for losses and obsolescence (93,165 ) (83,900 ) Net inventory $ 284,908 $ 271,871

Note 4 - Intangible Assets (Tab

Note 4 - Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2015
Notes Tables
Schedule of Finite-Lived Intangible Assets [Table Text Block]	2015 2014 Patents, at cost $ 3,502,135 $ 3,502,135 Less accumulated amortization (3,195,379 ) (2,888,622 ) Net intangible assets $ 306,756 $ 613,513
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	Years ending December 31, Amount 2016 306,756 Total $ 306,756
Schedule of Amortization Period for Intangible Assets [Table Text Block]	Amount Weighted Average Period (Years) Patents $ 3,502,135 11.4

Note 5 - Accrued expenses (Tabl

Note 5 - Accrued expenses (Tables)	12 Months Ended
	Dec. 31, 2015
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	2015 2014 Accrued executive severance $ 100,000 $ 100,000 Accrued audit and tax preparation 93,500 55,500 Accrued legal professional fees 76,500 111,600 Accrued outside services 58,813 - Accrued clinical study expenses 22,777 64,464 Accrued board of director's fees - 12,000 Accrued other 7,784 25,892 $ 359,374 $ 369,456

Note 6 - Notes Payable, Relat29

Note 6 - Notes Payable, Related Parties (Tables)	12 Months Ended
	Dec. 31, 2015
Notes Tables
Schedule of Maturities of Long-term Debt [Table Text Block]	Years ending December 31, Amount 2016 $ - 2017 5,372,743 Total $ 5,372,743

Note 7 - Income Taxes (Tables)

Note 7 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2015
Notes Tables
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	2015 2014 Current: Federal $ - $ - State - - Foreign - - - - Deferred: Federal (1,605,319 ) (2,198,311 ) State (176,377 ) (241,530 ) Foreign 2,419 9,532 Deferred Tax True Up 1,803,402 - Change in valuation allowance (24,125 ) 2,430,309 $ - $ -
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	2015 2014 Tax expense (benefit) at statutory rate $ (1,683,600 ) $ (2,090,928 ) Increase (reduction) in income taxes resulting from: State income taxes (benefit), net of federal benefit (119,778 ) (148,758 ) Non-deductible gain on warrant valuation adjustment (19,895 ) (156,011 ) Income from foreign subsidiaries 12,330 16,615 Deferred tax true up 1,803,402 - Change in valuation allowance - United States (24,125 ) 2,439,841 Other 31,666 (60,759 ) Income tax expense (benefit) $ - $ -
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	2015 2014 Deferred tax assets: Net operating loss carryforwards $ 26,451,449 $ 24,919,846 Net operating loss carryforwards - foreign 127,578 129,997 Excess of tax basis over book value of property and equipment 20,158 20,685 Excess of tax basis over book value of intangible assets 443,597 439,569 Stock-based compensation 1,834,172 3,447,183 Accrued employee compensation 90,442 37,736 Captialized equity costs 75,471 75,471 Inventory reserve 35,156 31,661 29,078,023 29,102,148 Valuation allowance (29,078,023 ) (29,102,148 ) Net deferred tax assets $ - $ -
Summary of Operating Loss Carryforwards [Table Text Block]	Years ending December 31, Amount 2025 $ 1,376,740 2026 7,291,084 2027 12,280,771 2028 6,922,963 2029 4,816,700 2030 7,667,557 2031 8,816,976 2032 4,768,716 2033 5,413,661 2034 6,663,638 2035 4,077,996 Total $ 70,096,802

Note 10 - Warrants (Tables)

Note 10 - Warrants (Tables)	12 Months Ended
	Dec. 31, 2015
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Warrant class Outstanding as of December 31, 2013 Issued Exercised Expired Outstanding as of December 31, 2014 Issued Exercised Expired Outstanding as of December 31, 2015 Class A Warrants 1,106,627 - - (1,106,627 ) - - - - - Class B Warrants 1,106,627 - - (1,106,627 ) - - - - - Class E Warrants 3,576,737 - - - 3,576,737 - - - 3,576,737 Class F Warrants 300,000 - - - 300,000 - - - 300,000 Class G Warrants 1,503,409 - - - 1,503,409 - - - 1,503,409 Class H Warrants 1,988,095 - - - 1,988,095 - - - 1,988,095 Class I Warrants 1,043,646 - - - 1,043,646 - - - 1,043,646 Class J Warrants - 629,378 - - 629,378 - - - 629,378 Class K Warrants - - - - - 3,310,000 - - 3,310,000 Series A Warrants - 25,951,421 - - 25,951,421 - - - 25,951,421 Series B Warrants - 15,570,852 - - 15,570,852 - - (15,570,852 ) - 10,625,141 42,151,651 - (2,213,254 ) 50,563,538 3,310,000 - (15,570,852 ) 38,302,686
Schedule Of Warrant Exercise Price And Expiration Date [Table Text Block]	Exercise Expiration price/share date Class A Warrants $ 4.00 September 2014 Class B Warrants $ 8.00 September 2014 Class E Warrants $ 4.00 April 2016 Class F Warrants $ 0.35 February 2018 Class G Warrants $ 0.80 July 2018 Class H Warrants $ 0.80 July 2018 Class I Warrants $ 0.85 September 2018 Class J Warrants $ 0.44 February 2019 Class K Warrants $ 0.55 June 2025 Series A Warrants $ 0.50 March 2019 Series B Warrants $ 1.50 March 2015

Note 12 - Stock-based Compens32

Note 12 - Stock-based Compensation (Tables)	12 Months Ended
	Dec. 31, 2015
Notes Tables
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	2015 2014 Weighted average expected life in years 5.0 5.4 Weighted average risk free interest rate 1.42 % 1.81 % Weighted average volatility 120.63 % 136.11 % Forfeiture rate 0.0 % 0.0 % Expected dividend yield 0.0 % 0.0 %
Schedule of Unrecognized Compensation Cost, Nonvested Awards [Table Text Block]	Unrecognized Compensation Years ending December 31, Cost 2016 $ 6,000 Total $ 6,000
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	Weighted Average Exercise Price Options per share Outstanding at December 31, 2013 8,366,830 $ 1.17 Granted 1,050,000 $ 0.55 Exercised (60,000 ) $ 0.21 Cancelled - $ - Forfeited or expired (2,150,000 ) $ 0.41 Outstanding at December 31, 2014 7,206,830 $ 1.31 Granted 4,950,000 $ 0.35 Exercised - $ - Cancelled - $ - Forfeited or expired (2,083,445 ) $ 2.39 Outstanding at December 31, 2015 10,073,385 $ 0.62 Vested and exercisable at December 31, 2015 9,898,383 $ 0.62
Schedule of Other Share-based Compensation, Activity [Table Text Block]	Weighted Average Exercise Price Options per share Outstanding at December 31, 2013 3,254,092 $ 0.35 Granted 1,050,000 $ 0.55 Vested (1,464,551 ) $ 0.41 Cancelled - $ - Forfeited or expired (1,924,999 ) $ 0.39 Outstanding at December 31, 2014 914,542 $ 0.37 Granted 4,950,000 $ 0.35 Vested (5,672,874 ) $ 0.36 Cancelled - $ - Forfeited or expired (16,666 ) $ 0.55 Outstanding at December 31, 2015 175,002 $ 0.36

Note 13 - Changes in Other Co33

Note 13 - Changes in Other Comprehensive Income (Loss) (Tables)	12 Months Ended
	Dec. 31, 2015
Notes Tables
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]	Currency Translations Total Balance, at December 31, 2013 $ 6,688 $ 6,688 Net change in other comprehensive loss (19,165 ) (19,165 ) Balance, at December 31, 2014 (12,477 ) (12,477 ) Net change in other comprehensive loss (20,685 ) (20,685 ) Balance, at December 31, 2015 $ (33,162 ) $ (33,162 )

Note 1 - Going Concern (Details

Note 1 - Going Concern (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Net Income (Loss) Attributable to Parent	$ (4,810,285)	$ (5,974,080)
Net Cash Provided by (Used in) Operating Activities	(3,473,456)	(6,678,369)
Working Capital	(851,805)
Stockholders' Equity Attributable to Parent	(5,877,836)	(1,551,400)	$ (6,127,881)
Cash and Cash Equivalents, at Carrying Value	$ 152,930	$ 3,547,071	$ 182,315

Note 2 - Summary of Significa35

Note 2 - Summary of Significant Accounting Policies (Details Textual)	12 Months Ended
	Dec. 31, 2015USD ($)shares	Dec. 31, 2014USD ($)shares
Customer Concentration Risk [Member] | Sales Revenue, Goods, Net [Member] | Customer One [Member]
Concentration Risk, Percentage	37.00%	26.00%
Customer Concentration Risk [Member] | Sales Revenue, Goods, Net [Member] | Customer Two [Member]
Concentration Risk, Percentage	29.00%	34.00%
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Customer One [Member]
Concentration Risk, Percentage	63.00%	24.00%
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Customer Two [Member]
Concentration Risk, Percentage	10.00%	34.00%
Patents [Member]
Finite-Lived Intangible Asset, Useful Life	11 years 146 days
Number Of Major Customers	2	2
Accounts Receivable Length Of Collection Period	60 days
Finite-Lived Intangible Asset, Useful Life	11 years 146 days
Notes Payable, Related Parties, Noncurrent	$ 5,348,112
Embedded Derivative, Loss on Embedded Derivative	$ 24,631
Notes Payable, Related Parties, Current		$ 5,372,743
Related Party Transaction, Rate	8.00%
Notes Payable, Fair Value Disclosure	$ 4,844,792	$ 5,221,985
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | shares	48,376,071	60,100,368
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	3 years

Note 2 - Fair Value of Derivati

Note 2 - Fair Value of Derivative Liabilities (Details)	12 Months Ended
	Dec. 31, 2015USD ($)
Balance	$ 159,626
New issuances	36,989
Fair Value Adjustment of Warrants	(58,515)
Balance	$ 138,100

Note 3 - Inventory Components (

Note 3 - Inventory Components (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Inventory - finished goods	$ 290,623	$ 263,027
Inventory - parts	87,450	92,744
Gross inventory	378,073	355,771
Provision for losses and obsolescence	(93,165)	(83,900)
Net inventory	$ 284,908	$ 271,871

Note 4 - Intangible Assets (Det

Note 4 - Intangible Assets (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Amortization of Intangible Assets	$ 306,757	$ 306,756

Note 4 - Summary of Intangible

Note 4 - Summary of Intangible Assets (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Patents, at cost	$ 3,502,135	$ 3,502,135
Less accumulated amortization	(3,195,379)	(2,888,622)
Net intangible assets	$ 306,756	$ 613,513

Note 4 - Amortization Expense (

Note 4 - Amortization Expense (Details)	Dec. 31, 2015USD ($)
2,016	$ 306,756
Net intangible assets	$ 306,756

Note 4 - Weighted Average Amort

Note 4 - Weighted Average Amortization Period for Intangible Assets (Details)	12 Months Ended
	Dec. 31, 2015USD ($)
Patents	$ 3,502,135
Finite-Lived Intangible Asset, Useful Life	11 years 146 days

Note 5 - Accrued expenses (Deta

Note 5 - Accrued expenses (Details Textual) - USD ($)	Nov. 06, 2012	Dec. 31, 2014
President [Member]
Bonus Payment Amount to Be Paid Upon Each of Four Bonus Payment Events	$ 100,000
Payments of Accrued Executive Severance Costs		$ 300,000

Note 5 - Summary of Accrued Exp

Note 5 - Summary of Accrued Expenses (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Accrued executive severance	$ 100,000	$ 100,000
Accrued audit and tax preparation	93,500	55,500
Accrued legal professional fees	76,500	$ 111,600
Accrued outside services	58,813
Accrued clinical study expenses	$ 22,777	$ 64,464
Accrued board of director's fees		12,000
Accrued other	$ 7,784	25,892
	$ 359,374	$ 369,456

Note 6 - Notes Payable, Relat44

Note 6 - Notes Payable, Related Parties (Details Textual) - USD ($)	Jun. 15, 2015	Dec. 31, 2015	Dec. 31, 2014
Health Tronics, Inc [Member] | Note Amendment [Member]
Related Party Transaction, Rate	8.00%
Related Party, Notes Payable Manditory Prepayment Rate	20.00%
Health Tronics, Inc [Member] | Class K Warrants [Member]
Class of Warrant or Right, Issued During Period	3,310,000
Common Stock, Par or Stated Value Per Share	$ 0.001
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.55
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	1
Class of Warrant or Right, Expiration Period	10 years
Health Tronics, Inc [Member]
Related Party Transaction, Rate		6.00%
Notes Payable, Related Parties, Noncurrent		$ 5,348,112
Debt Instrument, Unamortized Discount		24,631
Notes Payable, Related Parties, Current			$ 5,372,743
Common Stock, Par or Stated Value Per Share	$ 0.001
Interest Payable, Current		239,803	81,864
Interest Expense, Related Party		$ 413,200	$ 325,804
Class K Warrants [Member]
Class of Warrant or Right, Issued During Period		3,310,000
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.55
Related Party Transaction, Rate		8.00%
Notes Payable, Related Parties, Noncurrent		$ 5,348,112
Notes Payable, Related Parties, Current			$ 5,372,743
Class of Warrant or Right, Issued During Period		3,310,000	42,151,651
Common Stock, Par or Stated Value Per Share		$ 0.001	$ 0.001

Note 6 - Maturities on Notes Pa

Note 6 - Maturities on Notes Payable, Related Parties (Details) - Health Tronics, Inc [Member]	Dec. 31, 2015USD ($)
2,017	$ 5,372,743
Total	$ 5,372,743

Note 7 - Income Taxes (Details

Note 7 - Income Taxes (Details Textual)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	35.00%	35.00%

Note 7 - Income Tax Provision (

Note 7 - Income Tax Provision (Benefit) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Current:
Federal
State
Foreign
Deferred:
Federal	$ (1,605,319)	$ (2,198,311)
State	(176,377)	(241,530)
Foreign	2,419	$ 9,532
Deferred Tax True Up	1,803,402
Change in valuation allowance	$ (24,125)	$ 2,430,309

Note 7 - Reconciliation of Inco

Note 7 - Reconciliation of Income Tax Provision (Benefit) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Warrant [Member]
Increase (reduction) in income taxes resulting from:
Non-deductible gain on warrant valuation adjustment	$ (19,895)	$ (156,011)
Tax expense (benefit) at statutory rate	(1,683,600)	(2,090,928)
State income taxes (benefit), net of federal benefit	(119,778)	(148,758)
Income from foreign subsidiaries	12,330	$ 16,615
Deferred Tax True Up	1,803,402
Change in valuation allowance - United States	(24,125)	$ 2,439,841
Other	$ 31,666	$ (60,759)
Income tax expense (benefit)

Note 7 - Deferred Tax Assets (D

Note 7 - Deferred Tax Assets (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Deferred tax assets:
Net operating loss carryforwards	$ 26,451,449	$ 24,919,846
Net operating loss carryforwards - foreign	127,578	129,997
Excess of tax basis over book value of property and equipment	20,158	20,685
Excess of tax basis over book value of intangible assets	443,597	439,569
Stock-based compensation	1,834,172	3,447,183
Accrued employee compensation	90,442	37,736
Captialized equity costs	75,471	75,471
Inventory reserve	35,156	31,661
	29,078,023	29,102,148
Valuation allowance	(29,078,023)	(29,102,148)
Net deferred tax assets	$ 0	$ 0

Note 7 - Federal Net Operating

Note 7 - Federal Net Operating Loss Carryforwards (Details)	Dec. 31, 2015USD ($)
Expires in 2025 [Member]
Federal Net Operating Loss Carryforwards	$ 1,376,740
Expires in 2026 [Member]
Federal Net Operating Loss Carryforwards	7,291,084
Expires in 2027 [Member]
Federal Net Operating Loss Carryforwards	12,280,771
Expires in 2028 [Member]
Federal Net Operating Loss Carryforwards	6,922,963
Expires in 2029 [Member]
Federal Net Operating Loss Carryforwards	4,816,700
Expires in 2030 [Member]
Federal Net Operating Loss Carryforwards	7,667,557
Expires in 2031 [Member]
Federal Net Operating Loss Carryforwards	8,816,976
Expires in 2032 [Member]
Federal Net Operating Loss Carryforwards	4,768,716
Expires in 2033 [Member]
Federal Net Operating Loss Carryforwards	5,413,661
Expires in 2034 [Member]
Federal Net Operating Loss Carryforwards	6,663,638
Expires in 2035 [Member]
Federal Net Operating Loss Carryforwards	4,077,996
Federal Net Operating Loss Carryforwards	$ 70,096,802

Note 8 - Equity Transactions (D

Note 8 - Equity Transactions (Details Textual) - USD ($)

May. 27, 2014

Mar. 17, 2014

Feb. 18, 2014

Feb. 10, 2014

Dec. 23, 2013

Nov. 27, 2012

Mar. 31, 2014

Mar. 07, 2014

May. 31, 2014

Dec. 31, 2015

Dec. 31, 2014

Dec. 31, 2013

Feb. 15, 2013

Jan. 31, 2013

8% Convertible Promissory Notes [Member] | Class J Warrants [Member]

Class of Warrant or Right, Period After Which Warrant or Right is Exercisable

180 days

Class of Warrant or Right, Issued During Period

629,378

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 0.4425

Class of Warrant or Right, Expiration Period

5 years

8% Convertible Promissory Notes [Member] | During First Sixty Days [Member]

Debt Instrument, Prepayment Amount as a Percentage of Outstanding Balance

120.00%

8% Convertible Promissory Notes [Member]

Convertible promissory note rate

8.00%

Debt Instrument, Face Amount

$ 278,500

Proceeds from Convertible Debt

$ 250,000

Debt Instrument, Original Issuance Discount Percent

10.00%

Debt Instrument, Original Issuance Discount

$ 25,000

Debt Instrument, Prepayment Term

180 days

Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger

75.00%

Debt Instrument, Convertible, Threshold Trading Days

20

Repayments of Convertible Debt

$ 337,171

Payment of Prepayment Penalty

56,195

18% Convertible Promissory Notes [Member] | Series A Warrants [Member]

Class of Warrant or Right, Outstanding

2,055,421

18% Convertible Promissory Notes [Member] | Series B Warrants [Member]

Class of Warrant or Right, Outstanding

1,233,252

18% Convertible Promissory Notes [Member] | Michael N. Nemelka [Member]

Due to Related Parties

$ 110,000

18% Convertible Promissory Notes [Member]

Convertible promissory note rate

18.00%

18.00%

Debt Instrument, Face Amount

$ 1,000,000

Proceeds from Convertible Debt

$ 815,000

Debt Instrument, Term

270 days

Debt Instrument, Convertible, Conversion Price

$ 0.55

Convertible Debt

$ 822,168

Debt Conversion, Converted Instrument, Shares Issued

1,644,337

One Hundred Twenty Eight Thousand Five Hundred Dollars Convertible Note [Member] | During First Sixty Days [Member]

Debt Instrument, Prepayment Amount as a Percentage of Outstanding Balance

115.00%

One Hundred Twenty Eight Thousand Five Hundred Dollars Convertible Note [Member]

Convertible promissory note rate

8.00%

8.00%

Debt Instrument, Face Amount

$ 128,500

$ 128,500

Proceeds from Convertible Debt

$ 125,000

Debt Instrument, Prepayment Term

180 days

Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger

61.00%

Debt Instrument, Convertible, Threshold Trading Days

10

Repayments of Convertible Debt

158,055

Payment of Prepayment Penalty

29,555

$78,500 Convertible Note [Member] | During First Sixty Days [Member]

Debt Instrument, Prepayment Amount as a Percentage of Outstanding Balance

115.00%

$78,500 Convertible Note [Member]

Debt Instrument, Face Amount

$ 78,500

Proceeds from Convertible Debt

$ 75,000

Debt Instrument, Prepayment Term

180 days

Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger

61.00%

Debt Instrument, Convertible, Threshold Trading Days

10

Repayments of Convertible Debt

90,275

Payment of Prepayment Penalty

$ 11,775

Class J Warrants [Member]

Class of Warrant or Right, Issued During Period

629,378

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 0.44

Class of Warrant or Right, Outstanding

629,378

629,378

Series A Warrants [Member] | Private Placement [Member] | Common Stock [Member]

Class of Warrant or Right, Number of Securities Called by Each Warrant or Right

1

Series A Warrants [Member] | Private Placement [Member] | Newport Coast Securities, Inc. and Oppenheimer & Co. Inc. [Member]

Class of Warrant or Right, Outstanding

696,000

Series A Warrants [Member] | Private Placement [Member]

Class of Warrant or Right, Issued During Period

23,200,000

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 0.50

Class of Warrant or Right, Expiration Period

5 years

Series A Warrants [Member]

Class of Warrant or Right, Issued During Period

25,951,421

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 0.50

Class of Warrant or Right, Outstanding

25,951,421

25,951,421

Series B Warrants [Member] | Private Placement [Member] | Common Stock [Member]

Class of Warrant or Right, Number of Securities Called by Each Warrant or Right

1

Warrants Term

1 year

Series B Warrants [Member] | Private Placement [Member] | Newport Coast Securities, Inc. and Oppenheimer & Co. Inc. [Member]

Class of Warrant or Right, Outstanding

417,600

Series B Warrants [Member] | Private Placement [Member]

Class of Warrant or Right, Issued During Period

13,920,000

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 1.50

Series B Warrants [Member]

Class of Warrant or Right, Issued During Period

15,570,852

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 1.50

Class of Warrant or Right, Outstanding

15,570,852

Private Placement [Member] | Series A Preferred Stock [Member]

Stock Issued During Period, Shares, New Issues

6,175

Convertible Preferred Stock, Shares Issued upon Conversion

2,000

Private Placement [Member] | Board of Directors Chairman [Member]

Proceeds from Issuance of Private Placement

$ 50,000

Private Placement [Member] | Joseph Chiarelli [Member]

Proceeds from Issuance of Private Placement

40,000

Private Placement [Member] | Michael N. Nemelka [Member]

Proceeds from Issuance of Private Placement

$ 50,000

Private Placement [Member]

Stock Issued During Period, Shares, New Issues

6,210,000

Proceeds from Issuance of Private Placement Gross

$ 9,280,000

Proceeds from Issuance of Private Placement

8,562,500

Payments of Stock Issuance Costs

$ 717,500

Series A Preferred Stock [Member]

Stock Issued During Period, Shares, New Issues

6,175

Convertible Preferred Stock, Shares Issued upon Conversion

2,000

Common Stock [Member]

Stock Issued During Period, Shares, Issued for Services

1,208,000

Stock Issued During Period, Value, Issued for Services

$ 1,208

Subscription Agreement [Member] | On or before January 31, 2013 [Member]

Receivable from Shareholders or Affiliates for Issuance of Capital Stock

$ 50,000

Subscription Agreement [Member] | On or before February 15, 2013 [Member]

Receivable from Shareholders or Affiliates for Issuance of Capital Stock

$ 50,000

Subscription Agreement [Member] | On or before May 27, 2014 [Member]

Receivable from Shareholders or Affiliates for Issuance of Capital Stock

$ 900,000

Minimum Installment Amount Of Purchase Price

$ 100,000

Subscription Agreement [Member]

Stock Issued During Period, Shares, New Issues

3,600,000

Common Stock, Capital Shares Reserved for Future Issuance

4,000,000

Share Price

$ 0.25

Aggregate Sales Price For Common Stock

$ 1,000,000

Receivable from Shareholders or Affiliates for Issuance of Capital Stock

100,000

Available Cash Threshold

$ 100,000

Proceeds from Issuance of Common Stock

$ 900,000

Consulting Agreements [Member]

Stock Issued During Period, Shares, Issued for Services

1,005,000

Stock Issued During Period, Value, Issued for Services

$ 624,150

Proceeds from Issuance of Private Placement

$ 8,562,500

Class of Warrant or Right, Issued During Period

3,310,000

42,151,651

Class of Warrant or Right, Outstanding

38,302,686

50,563,538

10,625,141

Proceeds from Convertible Debt

$ 325,000

Repayments of Convertible Debt

450,000

Stock Issued During Period, Value, Issued for Services

$ 743,150

Note 9 - Preferred Stock (Detai

Note 9 - Preferred Stock (Details Textual) - USD ($)	Jan. 06, 2015	Mar. 17, 2014	Dec. 31, 2014	Dec. 31, 2015
Series A Preferred Stock [Member]
Preferred Stock, Shares Outstanding	0
Preferred Stock, Shares Authorized				6,175
Preferred Stock, Par or Stated Value Per Share				$ 0.001
Preferred Stock, Stated Value Per Share				$ 1,000
Stock Issued During Period, Shares, New Issues		6,175
Convertible Preferred Stock, Shares Issued upon Conversion				2,000
Convertible Preferred Stock Beneficial Ownership Limitation Conversion Percentage				9.99%
Conversion of Stock, Shares Converted	1,165		5,010
Undesignated Preferred Stock [Member]
Preferred Stock, Shares Outstanding			0	0
Preferred Stock, Shares Authorized			4,993,825	4,993,825
Preferred Stock, Par or Stated Value Per Share			$ 0.001	$ 0.001
Common Stock [Member]
Conversion of Stock, Shares Issued	2,330,000		10,020,000

Note 10 - Warrants (Details Tex

Note 10 - Warrants (Details Textual) - USD ($)	Jun. 15, 2015	Feb. 28, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2015	Dec. 31, 2014	Mar. 17, 2014	Mar. 07, 2014	Feb. 10, 2014
Class F Warrants [Member]
Class of Warrant or Right, Issued During Period		2,000,000
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.35			$ 0.35
Warrants Term		5 years
Warrants Vested During Period		300,000
Warrants Vesting Contingent Upon Captial Raise Completion		1,700,000
Capital Raise Threshold For Vesting Of Warrants		$ 5,000,000
Class of Warrant or Right, Expired During Period				1,700,000
Class of Warrant or Right, Outstanding			300,000	300,000	300,000	300,000
Class K Warrants [Member] | Health Tronics, Inc [Member]
Class of Warrant or Right, Issued During Period	3,310,000
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.55
Common Stock, Par or Stated Value Per Share	$ 0.001
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	1
Class of Warrant or Right, Expiration Period	10 years
Class K Warrants [Member]
Class of Warrant or Right, Issued During Period					3,310,000
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 0.55
Class of Warrant or Right, Expired During Period
Class of Warrant or Right, Outstanding					3,310,000
Warrants and Rights Outstanding	$ 36,989
Class J Warrants [Member]
Class of Warrant or Right, Issued During Period						629,378
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 0.44
Class of Warrant or Right, Expired During Period
Class of Warrant or Right, Outstanding			629,378		629,378	629,378
Warrants and Rights Outstanding									$ 12,776
Series A and B Warrants [Member] | Private Placement [Member]
Warrants and Rights Outstanding							$ 557,733
Series A and B Warrants [Member] | 18% Convertible Promissory Notes [Member]
Warrants and Rights Outstanding									$ 47,974
Health Tronics, Inc [Member]
Common Stock, Par or Stated Value Per Share	$ 0.001
18% Convertible Promissory Notes [Member]
Convertible promissory note rate								18.00%	18.00%
Class of Warrant or Right, Issued During Period					3,310,000	42,151,651
Class of Warrant or Right, Expired During Period					15,570,852	2,213,254
Class of Warrant or Right, Outstanding			50,563,538	10,625,141	38,302,686	50,563,538
Common Stock, Par or Stated Value Per Share			$ 0.001		$ 0.001	$ 0.001
Adjustment to Interest Expense			$ 327,088
Fair Value Adjustment of Warrants			$ 458,857		$ (58,515)	$ (458,857)

Note 10 - Warrant Activity (Det

Note 10 - Warrant Activity (Details) - shares	7 Months Ended	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2015	Dec. 31, 2014
Class A Warrants [Member]
Warrants Outstanding (in shares)			1,106,627
Warrants Issued (in shares)
Warrants Expired (in shares)			(1,106,627)
Warrants Outstanding (in shares)	1,106,627
Class B Warrants [Member]
Warrants Outstanding (in shares)			1,106,627
Warrants Issued (in shares)
Warrants Expired (in shares)			(1,106,627)
Warrants Outstanding (in shares)	1,106,627
Class E Warrants [Member]
Warrants Outstanding (in shares)		3,576,737	3,576,737
Warrants Issued (in shares)
Warrants Expired (in shares)
Warrants Outstanding (in shares)	3,576,737	3,576,737	3,576,737
Class F Warrants [Member]
Warrants Outstanding (in shares)		300,000	300,000
Warrants Issued (in shares)
Warrants Expired (in shares)	(1,700,000)
Warrants Outstanding (in shares)	300,000	300,000	300,000
Class G Warrants [Member]
Warrants Outstanding (in shares)		1,503,409	1,503,409
Warrants Issued (in shares)
Warrants Expired (in shares)
Warrants Outstanding (in shares)	1,503,409	1,503,409	1,503,409
Class H Warrants [Member]
Warrants Outstanding (in shares)		1,988,095	1,988,095
Warrants Issued (in shares)
Warrants Expired (in shares)
Warrants Outstanding (in shares)	1,988,095	1,988,095	1,988,095
Class I Warrants [Member]
Warrants Outstanding (in shares)		1,043,646	1,043,646
Warrants Issued (in shares)
Warrants Expired (in shares)
Warrants Outstanding (in shares)	1,043,646	1,043,646	1,043,646
Class J Warrants [Member]
Warrants Outstanding (in shares)		629,378
Warrants Issued (in shares)			629,378
Warrants Expired (in shares)
Warrants Outstanding (in shares)		629,378	629,378
Class K Warrants [Member]
Warrants Outstanding (in shares)
Warrants Issued (in shares)		3,310,000
Warrants Expired (in shares)
Warrants Outstanding (in shares)		3,310,000
Series A Warrants [Member]
Warrants Outstanding (in shares)		25,951,421
Warrants Issued (in shares)			25,951,421
Warrants Expired (in shares)
Warrants Outstanding (in shares)		25,951,421	25,951,421
Series B Warrants [Member]
Warrants Outstanding (in shares)		15,570,852
Warrants Issued (in shares)			15,570,852
Warrants Expired (in shares)		(15,570,852)
Warrants Outstanding (in shares)			15,570,852
Warrants Outstanding (in shares)		50,563,538	10,625,141
Warrants Issued (in shares)		3,310,000	42,151,651
Warrants Expired (in shares)		(15,570,852)	(2,213,254)
Warrants Outstanding (in shares)	10,625,141	38,302,686	50,563,538

Note 10 - Warrant Exercise Pric

Note 10 - Warrant Exercise Price Per Share and Expiration Date (Details)	12 Months Ended
	Dec. 31, 2015$ / shares
Class A Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 4
Expiration date	September 2,014
Class B Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 8
Expiration date	September 2,014
Class E Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 4
Expiration date	April 2,016
Class F Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.35
Expiration date	February 2,018
Class G Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.80
Expiration date	July 2,018
Class H Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.80
Expiration date	July 2,018
Class I Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.85
Expiration date	September 2,018
Class J Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.44
Expiration date	February 2,019
Class K Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.55
Expiration date	June 2,025
Series A Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.50
Expiration date	March 2,019
Series B Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 1.50
Expiration date	March 2,015

Note 11 - Commitments and Con56

Note 11 - Commitments and Contingencies (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Operating Leases, Rent Expense, Net	$ 155,926	$ 132,814

Note 12 - Stock-based Compens57

Note 12 - Stock-based Compensation (Details Textual) - USD ($)	Oct. 01, 2015	Aug. 31, 2015	Apr. 28, 2015	May. 07, 2014	Apr. 04, 2014	Nov. 01, 2010	Dec. 31, 2015	Dec. 31, 2014
Stock Incentive Plan [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period						3 years
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period						10 years
Stock Incentive Plan [Member] | Active Employees and Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	1,900,000			900,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$ 0.11			$ 0.55
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 0.11			$ 0.48
Allocated Share-based Compensation Expense	$ 209,000
Allocated Share-based Compensation Expense, Net of Tax				$ 429,001
Stock Incentive Plan [Member] | Active Employees, Members of the Board of Directors, and Members of the Medical Advisory Board [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	1,450,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$ 0.50
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 0.10
Allocated Share-based Compensation Expense	$ 145,000
Stock Incentive Plan [Member] | Former CEO [Member]
Allocated Share-based Compensation Expense		$ 98,100
Stock Incentive Plan [Member] | Medical Advisory Board Member 1 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross			50,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price			$ 0.55
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value							$ 0.11
Allocated Share-based Compensation Expense							$ 11,107
Stock Incentive Plan [Member] | Two Members of the Medical Advisory Board [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross					75,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price					$ 0.55
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value					$ 0.24
Allocated Share-based Compensation Expense, Net of Tax					$ 35,625
Stock Incentive Plan [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit							$ 0.11	$ 0.11
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit							$ 2	$ 2
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value							$ 0	$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value							$ 0	$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized							12,500,000	8,500,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term							7 years 167 days	6 years 156 days
Employee Stock Option [Member]
Allocated Share-based Compensation Expense							$ 504,534	$ 135,015
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period							3 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross							4,950,000	1,050,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price							$ 0.35	$ 0.55

Note 12 - Fair Value Assumption

Note 12 - Fair Value Assumptions (Details)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Weighted average expected life in years	5 years	5 years 146 days
Weighted average risk free interest rate	1.42%	1.81%
Weighted average volatility	120.63%	136.11%
Forfeiture rate	0.00%	0.00%
Expected dividend yield	0.00%	0.00%

Note 12 - Unrecognized Compensa

Note 12 - Unrecognized Compensation Cost (Details)	Dec. 31, 2015USD ($)
Will Be Recognized in 2016 [Member]
2,016	$ 6,000
2,016	$ 6,000

Note 12 - Option Activity (Deta

Note 12 - Option Activity (Details) - $ / shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Outstanding, number (in shares)	7,206,830	8,366,830
Outstanding, weighted average exercise price per share (in dollars per share)	$ 1.31	$ 1.17
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	4,950,000	1,050,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$ 0.35	$ 0.55
Exercised (in shares)		(60,000)
Exercised, weighted average exercise price per share (in dollars per share)		$ 0.21
Forfeited or expired (in shares)	(2,083,445)	(2,150,000)
Forfeited or expired, weighted average exercise price per share (in dollars per share)	$ 2.39	$ 0.41
Outstanding, number (in shares)	10,073,385	7,206,830
Outstanding, weighted average exercise price per share (in dollars per share)	$ 0.62	$ 1.31
Forfeited or expired (in shares)	(2,083,445)	(2,150,000)
Vested and exercisable at December 31, 2015 (in shares)	9,898,383
Vested and exercisable, weighted average exercise price per share (in dollars per share)	$ 0.62

Note 12 - Nonvested Options Act

Note 12 - Nonvested Options Activity (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Outstanding, number (in shares)	914,542	3,254,092
Outstanding, weighted average exercise price per share (in dollars per share)	$ 0.37	$ 0.35
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	4,950,000	1,050,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$ 0.35	$ 0.55
Vested, number (in shares)	(5,672,874)	(1,464,551)
Vested weighted average exercise price per share (in dollars per share)	$ 0.36	$ 0.41
Forfeited or expired, number (in shares)		(1,924,999)
Forfeited or expired, weighted average exercise price per share		$ 0.39
Outstanding, number (in shares)	175,002	914,542
Outstanding, weighted average exercise price per share (in dollars per share)	$ 0.36	$ 0.37
Forfeited or expired, number (in shares)	(16,666)
Forfeited or expired, weighted average exercise price per share (in dollars per share)	$ 0.55

Note 13 - Other Comprehensive L

Note 13 - Other Comprehensive Loss (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Accumulated Foreign Currency Adjustment Attributable to Parent [Member]
Balance	$ (12,477)	$ 6,688
Net change in other comprehensive loss	(20,685)	(19,165)
Balance	(33,162)	(12,477)
Balance	(12,477)	6,688
Net change in other comprehensive loss	(20,685)	(19,165)
Balance	$ (33,162)	$ (12,477)

Note 14 - Segment and Geograp63

Note 14 - Segment and Geographic Information (Details Textual)	12 Months Ended
	Dec. 31, 2015
Number of Operating Segments	1

Note 15 - Subsequent Events (De

Note 15 - Subsequent Events (Details Textual)	Mar. 11, 2016USD ($)$ / sharesshares	Feb. 01, 2016USD ($)shares	Jan. 13, 2016$ / sharesshares	Mar. 17, 2014$ / sharesshares	Dec. 31, 2015$ / sharesshares	Dec. 31, 2014$ / sharesshares
Subsequent Event [Member] | The $58,300 Convertible Promissory Note [Member]
Debt Instrument, Face Amount | $		$ 58,300
Number Of Investors		2
Debt Instrument, Prepayment Term		60 years
Debt Instrument, Prepayment Amount as a Percentage of Outstanding Balance		120.00%
Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger		30.00%
Debt Instrument, Convertible, Threshold Trading Days		20
Subsequent Event [Member] | The $58,300 Convertible Promissory Notes and Warrants [Member]
Convertible promissory note rate		8.00%
Proceeds from Short-term Debt | $		$ 50,000
Debt Instrument, Original Issuance Discount Percent		10.00%
Subsequent Event [Member] | Private Placement [Member] | Class L Warrants [Member]
Class of Warrant or Right, Issued During Period	25,495,835
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 0.08
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right	1
Subsequent Event [Member] | Private Placement [Member] | Michael N. Nemelka [Member]
Sale of Stock, Consideration Received on Transaction | $	$ 100,000
Subsequent Event [Member] | Private Placement [Member]
Stock Issued During Period, Shares, New Issues	25,495,835
Stock Issued During Period, Value, New Issues | $	$ 1,529,750
Mandatory Prepayment of Principal on Related Party Note Payable, Percent of Proceeds	20.00%
Subsequent Event [Member] | Class M Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right		1
Warrants and Rights Outstanding | $		$ 58,300
Subsequent Event [Member] | Series A Warrants [Member] | Convertible Common Stock [Member]
Warrants Vested During Period			23,701,428
Shares, Issued			7,447,954
Convertible Preferred Stock, Shares Issued upon Conversion			12,500
Subsequent Event [Member] | Series A Warrants [Member] | Convertible Preferred Stock [Member]
Shares, Issued			293
Subsequent Event [Member] | Series A Warrants [Member]
Class of Warrant or Right, Exchange Ratio			0.4685
Common Stock, Ownership Threshold			9.99%
Subsequent Event [Member]
Common Stock, Par or Stated Value Per Share | $ / shares			$ 0.001
Preferred Stock, Par or Stated Value Per Share | $ / shares			$ 0.001
Private Placement [Member] | Series A Warrants [Member]
Class of Warrant or Right, Issued During Period				23,200,000
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares				$ 0.50
Private Placement [Member]
Stock Issued During Period, Shares, New Issues				6,210,000
Series A Warrants [Member]
Class of Warrant or Right, Issued During Period						25,951,421
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares					$ 0.50
Convertible Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share | $ / shares					$ 0.001	$ 0.001
Class of Warrant or Right, Issued During Period					3,310,000	42,151,651
Common Stock, Par or Stated Value Per Share | $ / shares					$ 0.001	$ 0.001